

1
2
3
4 **Comments on Chaloupka, Emery, and Liang**
5
6

7 Robert MacCoun
8
9
10

11 Frank Chaloupka has made major contributions to the empirical study of addictive drug use,
12 and he and his colleagues provide a valuable review of the growing economic literature on
13 addiction. Their paper documents recent movement away from the strict “rational addiction”
14 framework of Gary Becker and his colleagues, in the direction of models that correspond
15 more closely to recent psychological theorizing about addiction. This is a shift in orientation
16 as well as content. The newer theories tend to start with the behavior of addicts and try to
17 model it; Becker and colleagues started with a model (rational choice) and tried to make it
18 behave like an addict.

19 By focusing my brief comments on Becker’s rational addiction theory (RAT), I necessarily
20 exaggerate the differences between economics and psychology regarding addiction, because
21 Becker’s model is economics’ least psychological statement. Elsewhere, Peter Reuter and I
22 described RAT as “an intellectual *tour de force* of unknown relevance to the phenomenon of
23 real-world addiction” (MacCoun & Reuter 2001: 64). Here, writing without my economist
24 co-author, I am inclined to be less equivocal. There are good reasons to believe that RAT is
25 wrong as a model of the addiction process. But at the same time, I think it is a mistake to
26 dismiss its contribution to drug policy analysis.
27
28
29

30 **RAT as a Process Model of Addict Choice**
31

32 I will not rehearse the cogent points about RAT made in other papers in this volume (or in
33 Skog’s (1999a, b) sophisticated and fair-minded assessments). But in brief, there is now a
34 wealth of evidence suggesting that important aspects of RAT are almost certainly wrong.
35 First and foremost, in dozens of direct empirical tests, temporal discounting — by addicts,
36 non-addicted people, and animals — is better described by hyperbolic discounting than
37 by exponential discounting (see, e.g. Ainslie & Monterosso Chapter 1, Rachlin Chapter 4,
38 Skog Chapter 5, Cardinal *et al.* Chapter 6, Bickel and Johnson Chapter 8, Mitchell Chapter
39 11, this volume).¹ Exponential discounting implies, as Chaloupka and colleagues put it,
40 “that individuals consistently maximize utility over their life cycle.” Hyperbolic discounting
41 implies preference reversals over time.

42 Moreover, it is not at all clear that people — be they pension managers or heroin addicts
43 — have anything like a coherent “lifetime utility function.” The notion is contradicted by
44 much theory and evidence in cognitive psychology (see Kahneman & Tversky’s 2000 edited
45 collection), behavioral finance (e.g. Benartzi & Thaler 1995), and behavioral economics

1 (Rabin 2000; Rabin & Thaler 2001) showing a disconnect between our assessments of
 2 isolated, moment-by-moment choices and the way we might assess aggregated, lifetime
 3 utility — if we actually did so.

4 For example, Rabin (2000) has shown that the degree of concavity necessary to describe
 5 risk attitudes in low stake situations generates preposterous predictions for high stake
 6 choices. Rabin & Thaler (2001: 225) argue that “the correct conclusion for economists to
 7 draw, both from thought experiments and from actual data, is that people do not display
 8 a consistent coefficient of relative risk aversion, so it is a waste of time to try to measure
 9 it.” In fairness, this body of work does not examine drug addicts, but everything we know
 10 about addicts suggest less planning, not more, than recent studies find in college students
 11 and financial investors.

14 Price Matters

16 If I and others are correct that RAT is wrong as a process model of addict choice, then what
 17 are we to make of the moderate empirical success of the theory in econometric tests? RAT’s
 18 greatest empirical success, and its most important contribution, is the notion that addicts
 19 are sensitive to current drug prices. For the rationality debate, this is more molehill than
 20 mountain. Responsiveness to price is about as minimal a requirement for rationality as one
 21 could ask for. Pigeons are price-sensitive in the psychology laboratory; most animals are
 22 price-sensitive in ethological studies of foraging behavior in the wild.

23 But for policy analysis, addict sensitivity to prices is enormously useful information. For
 24 a long time, many of us had unthinkingly accepted the idea that addicts were so chemically
 25 enslaved that they’d obtain their daily dose at almost any cost. If addicts are indifferent
 26 to price, then any intervention that drives up the price of a drug will have unintended
 27 deleterious consequences — addicts will divert more of their income from the support of
 28 their household and dependents; they may commit more income-generating crime; and
 29 illegal drug traffickers or licit tobacco companies will earn more profits at the expense of
 30 public health.

31 Chaloupka and colleagues cite evidence that smokers engage in compensatory behavioral
 32 responses to tax and price increases, which would imply that “the perceived health benefits
 33 associated with higher cigarette taxes are likely to be somewhat overstated.” (For further
 34 evidence, see MacCoun & Reuter 2001, Chapter 15; Stratton *et al.* 2001.) Of course, a
 35 corollary is that these compensatory responses imply that estimates of price elasticity
 36 of demand probably overstate smokers’ willingness to reduce their habit in the face of
 37 rising prices. At least initially, smokers can reduce the quantity of tobacco they purchase
 38 without reducing the quantity of tars and nictines they consume, by inhaling deeper,
 39 holding the smoke in longer, or switching to brands with more tars or less efficient
 40 filters.

41 The behavioral economics literature suggests that there may be better ways to model
 42 addiction than the RAT account, but Becker and his colleagues surely deserve credit for
 43 establishing price as an important variable in a literature previously dominated by classical
 44 conditioning cues, faulty parenting, peer pressure, and other variables less amenable to
 45 aggregate measurement and forecasting.

1 **Back to the Future**

2
3 Accepting that current prices matter is quite different from accepting that *future* prices
4 matter. Chaloupka, Emery, and Laing review evidence that future prices are associated with
5 current tobacco consumption, and following Becker and colleagues, they interpret this as
6 an indication that users form rational expectations and incorporate those expectations into
7 their current choices. I do not contest the notion that addicts, like non-addicts, sometimes
8 consider the future consequences of their actions. As a father of two young children,
9 I am quite preoccupied with college tuition levels two decades from now. Because it
10 clearly affects my concerns about how to pay for their education, rather than my decision
11 about whether to pay for it, there's a temptation to say, "Well, of course, but that's your
12 child's education, not your cigarette (coffee, cocaine, etc.) habit." But, of course, that
13 response begs the question that we are asking: Just how important is the addict's habit to
14 the addict?

15 Economists who believe in rational expectations need to shoulder more of the burden of
16 proof here. Our understanding of hyperbolic discounting and temporal myopia, as well as a
17 rich ethnographic literature on addict behavior, make it hard to swallow the idea that future
18 price changes play anything but a trivial role in addicts' current choices.

19 If addicts aren't considering future prices, why are future prices associated with current
20 use? Future prices might be an econometric proxy for unobserved concurrent rational
21 expectations about the future. But they might also be a proxy for a host of other concurrent
22 factors that are correlated with future prices.² Tobacco prices can increase because of
23 rising agricultural and other business costs. But they can also rise because of increases in
24 tobacco taxes.³ It takes tremendous political mobilization to raise "sin" taxes in the face of
25 powerful industry opposition (see MacCoun & Reuter 2001, Chapter 8). How can we be
26 sure it is the anticipated price rise, rather than the impassioned anti-smoking campaigns,
27 that is producing reductions in current consumption? One could make a similar argument
28 at a smaller scale about price increases due to rising tort litigation expenses.

29 So if future prices are associated with current consumption, the burden would seem to lie
30 with RAT theorists to do more to show that this indicates a rational expectation effect. On
31 the dependent measure side, one would like to see direct measures of perceived expectations
32 about cigarette prices, and statistical evidence that such expectations mediate the "effect" of
33 future prices on current consumption.⁴ On the independent variable side, one might test the
34 differential "effects" of future tax increases vs. non-tax price increases, and the effects of
35 tax initiatives vs. non-tax anti-smoking campaigns. One could operationalize anti-tobacco
36 campaigns using advertising budgets, minutes of radio and TV airtime, newspaper column
37 inches, and so on. Supplementing U.S. data with evidence from other nations might provide
38 more variance in tax levels and price trends.

41 **Tobacco is Different**

42
43 Chaloupka and his colleagues have published important studies of illicit drug use, but their
44 review indicates that most of the econometric work on addiction has focused on tobacco.
45 From a public health standpoint, this focus makes great sense, as tobacco's health harms

1 swamp those of the other drugs. And from a methodological standpoint, there's no question
2 that tobacco data are far richer and more reliable than data on illicit drug use. Still, the heavy
3 focus on tobacco does create some inferential problems.

4 On the demand side, tobacco differs from other addictive drugs in many ways. It is less
5 intoxicating and more easily integrated into daily activities than other drugs (at least outside
6 the U.S.!). Until recently, the costs it imposed on others were not seen as a significant factor,
7 so anti-smoking stigma is far less developed than, say, anti-heroin stigma. And nicotine is
8 probably more dependency-promoting than many drugs, a fact that probably strengthens
9 the case that Becker, Chaloupka and others are making about rationality; if nicotine is more
10 addictive than other drugs and tobacco addicts appear rational, there is an *a fortiori* case
11 that other addicts might be rational too.

12 On the supply side, the fact that tobacco is legal makes the case for generalization more
13 daunting. Tobacco can be readily purchased in many different locations (no network or
14 dealer contacts needed). Tobacco prices are surely lower than they would be in an illicit
15 market. Tobacco users are far less likely to be criminally active than, say, heroin addicts,
16 who often commit crimes to raise money for their habit, and who by definition are willing
17 to break the law. We know far less about the case for rational addiction involving illegal
18 drugs, and the data (especially on prices) are far noisier (Manski *et al.* 2001).

19 From a policy perspective, the fact that tobacco is legal means that it can be advertised
20 and promoted, and it can be regulated and taxed. Regulation creates a host of policy
21 levers unavailable to the prohibitionist (MacCoun *et al.* 1996). Because taxes and other
22 price controls are possible, the rational addiction formulation has clear policy relevance.
23 But the policy implications for a prohibition regime are far murkier. If correct, RAT
24 encourages us to drive up drug prices, since that should reduce consumption with little
25 increase in income-generating crime. But our only mechanisms for doing so are the various
26 forms of supply reduction: interdiction, source-country controls, aggressive enforcement
27 against street dealers. And there are serious questions about whether these efforts actually
28 reduce illicit drug supplies to any significant degree, and whether the benefits outweigh
29 the collateral damage (see Caulkins & MacCoun in press; Manski *et al.* 2001; Reuter
30 *et al.* 1988).

31 32 33 Notes

34
35 1. In their paper, Chaloupka and colleagues describe Laibson's model as hyperbolic, and Ainslie's
36 model as quasi-hyperbolic. In fact, it is the other way around. Laibson's model comes closer to a step
37 function; it is more tractable but fails to capture some empirical subtleties of discounting behavior.

38 2. One possibility is that price increases are a response to current prevalence, though I think at
39 least some analyses rule this out.

40 3. Over the period 1985–2000, average real tobacco prices (excluding tobacco taxes) have risen
41 100%, while average combined state and federal tobacco taxes have risen 56%. (Rosalie Pacula,
42 Senior Economist at RAND, personal communication on 30 January 2003.)

43 4. Specifically, current consumption should be correlated more strongly with expected future prices
44 than with actual future prices, because expected prices are the intermediate causal link and because if
45 prices diverge from expectations, it is the expectations that should drive choices. See Baron & Kenny
(1986).

References

- 1
2
3 Baron, R. M., & Kenny, D. A. (1986). The moderator-mediator variable distinction in social psy-
4 chological research: Conceptual, strategic, and statistical considerations. *Journal of Personality &*
5 *Social Psychology*, *51*, 1173–1182.
- 6 Benartzi, S., & Thaler, R. H. (1995). Myopic loss aversion and the equity premium puzzle. *Quarterly*
7 *Journal of Economics*, *110*, 73–92.
- 8 Caulkins, J., & MacCoun, R. J. (in press). Limited rationality and the limits of supply reduction.
9 *Journal of Drug Issues*.
- 10 Kahneman, D., & Tversky, A. (Eds) (2000). *Choices, values, and frames*. Cambridge, UK: Cambridge
11 University Press.
- 12 MacCoun, R., & Reuter, P. (2001). *Drug war heresies: Learning from other vices, times, and places*.
13 New York: Cambridge University Press.
- 14 MacCoun, R., Reuter, P., & Schelling, T. (1996). Assessing alternative drug control regimes. *Journal*
15 *of Policy Analysis and Management*, *15*, 1–23.
- 16 Manski, C., Pepper, J., & Petrie, C. (2001). *Informing America's policy on illegal drugs: What we*
17 *don't know keeps hurting us*. Washington, DC: National Academy of Sciences.
- 18 Rabin, M. (2000). Risk aversion and expected-utility theory: A calibration theorem. *Econometrica*,
19 *68*, 1281–1292.
- 20 Rabin, M., & Thaler, R. (2001). Risk aversion. *Journal of Economic Perspectives*, *15*, 219–232.
- 21 Reuter, P., Crawford, G., & Cave, J. (1988). *Sealing the borders: The effects of increased military*
22 *participation in drug interdiction*. Santa Monica, CA: RAND.
- 23 Skog, O. J. (1999a). Rationality, irrationality, and addiction — Notes on Becker and Murphy's the-
24 ory of addiction. In: J. Elster, & O. J. Skog (Eds), *Getting hooked: Rationality and addiction*
25 (pp. 173–207). Cambridge, U.K.: Cambridge University Press.
- 26 Skog, O. J. (1999b). Hyperbolic discounting, willpower, and addiction. In: J. Elster (Ed.), *Addiction:*
27 *Entries and exits* (pp. 151–168).
- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45